2. Search Result
Search Result
Results for "

PAC1

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13523
    PAC-1
    5 Publications Verification

    Procaspase activating compound 1

    		 Caspase Autophagy Apoptosis Cancer
    PAC-1 is a procaspase-3 activator that induces apoptosis in cancer cells with an EC50 of 2.08 μM.
    <em>PAC-1</em>
  • HY-147557
    PAC1R antagonist 1

    		PACAP Receptor Neurological Disease
    PAC1R antagonist 1 (compound 3d) is a potent and orally active antagonist of PAC1 receptor. PAC1R antagonist 1 can inhibit pituitary adenylate cyclase-activating polypeptide (PACAP)- and nerve injury-induced allodynia [1].
    <em>PAC1</em>R antagonist <em>1</em>
  • HY-P99509
    Zelminemab

    AMG-301

    		 Adenylate Cyclase Neurological Disease
    Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor [1].
    Zelminemab
  • HY-133529
    PA-8

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC50 of 2 nM [1] .
    PA-8
  • HY-P0176
    PACAP (1-27), human, ovine, rat

    PACAP 1-27
    PACAP (1-27), human, ovine, rat (PACAP 1-27) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively [1].
    PACAP (<em>1</em>-27), human, ovine, rat
  • HY-P0176A
    PACAP (1-27), human, ovine, rat TFA
    2 Publications Verification

    PACAP 1-27 TFA

    		 PACAP Receptor Neurological Disease Metabolic Disease
    PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is the N-terminal fragment of PACAP-38, and is a potent PACAP receptor antagonist with IC50s of 3 nM, 2 nM and 5 nM for rat PAC1, rat VPAC1 and human VPAC2, respectively [1].
    PACAP (<em>1</em>-27), human, ovine, rat TFA
  • HY-129421
    PA-9

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain [1].
    PA-9
  • HY-P1845A
    PACAP-38 (31-38), human, mouse, rat TFA

    		ERK EGFR Reactive Oxygen Species Calcium Channel Neurological Disease
    PACAP-38 (31-38), human, mouse, rat TFA is a PAC1 receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca 2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research [1] .
    PACAP-38 (31-38), human, mouse, rat TFA
  • HY-P1845
    PACAP-38 (31-38), human, mouse, rat

    		ERK EGFR Reactive Oxygen Species Calcium Channel Neurological Disease
    PACAP-38 (31-38), human, mouse, rat is a PAC1 receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca 2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research [1] .
    PACAP-38 (31-38), human, mouse, rat
  • HY-RS09955
    PACS1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PACS1 Human Pre-designed siRNA Set A contains three designed siRNAs for PACS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PACS1 Human Pre-designed siRNA Set A
    PACS1 Human Pre-designed siRNA Set A
  • HY-129937
    (S)-GNE-987

    		PROTACs Epigenetic Reader Domain Cancer
    (S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC) .
    (S)-GNE-987
  • HY-129937A
    GNE-987

    		PROTACs Epigenetic Reader Domain Cancer
    GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50=4.7 and 4.4 nM, respectively). GNE-987 incorporates a potent BET binder/inhibitor, a VHL-binding fragment, and a ten methylene spacer moiety. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC) .
    GNE-987

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: